PP
TPST icon

PDT Partners’s Tempest Therapeutics TPST Stock Holding History

PDT Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13
Closed -$57K – 531
2016
Q4 		$57K Sell
13
-14
-52% -$174K ﹤0.01% 492
2016
Q3 		$557K Buy
+27
New +$488K 0.03% 361
2015
Q4 		– Sell
-7
Closed -$169K – 922
2015
Q3 		$169K Buy
+7
New +$471K ﹤0.01% 1183

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PDT Partners's TPST Position: Q1 2017 in Review

PDT Partners sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 13 shares — an estimated $57K sold.

PDT Partners first reported a position in TPST in Q3 2015 and held it in 3 quarters. The position peaked at $557K in Q3 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

  • PDT Partners reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
  • PDT Partners sold 13 Tempest Therapeutics shares in Q1 2017, an estimated $57K.
  • PDT Partners first reported a position in Tempest Therapeutics in Q3 2015 and held it in 3 quarters.
  • PDT Partners's Tempest Therapeutics position peaked at $557K in Q3 2016.
  • 63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on PDT Partners's 13F filing for Q1 2017, filed 15 May 2017.